Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic PBPC transplantation in children.

A Verdeguer1, M Bermudez, J De la Rubia

  • 1Pediatric Oncology Unit, Hospital Universitario La Fe, Valencia, Spain.

Cytotherapy
|July 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Blood cancer journal·2024
Same author

Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2022
Same author

The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2021
Same author

Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.

European journal of cancer (Oxford, England : 1990)·2020
Same author

Distribution of segmental chromosomal alterations in neuroblastoma.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020
Same author

Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020
Same journal

Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome.

Cytotherapy·2026
Same journal

Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Cytotherapy·2026
Same journal

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Cytotherapy·2026
Same journal

Manufacturing strategies for prolonged CAR-T cell persistence.

Cytotherapy·2026
Same journal

Overcoming five main challenges to targeting hematologic malignancies.

Cytotherapy·2026
Same journal

Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field.

Cytotherapy·2026
See all related articles

Allogeneic peripheral blood stem cell transplantation is safe and effective in children. This study shows successful engraftment and good outcomes in pediatric patients receiving stem cells from related donors.

Area of Science:

  • Pediatric Hematology
  • Stem Cell Transplantation
  • Oncology

Background:

  • Limited published data exists on pediatric donor-recipient pairs for allogeneic transplantation.
  • Peripheral Blood Progenitor Cells (PBPC) are increasingly used in allotransplantation.

Purpose of the Study:

  • To evaluate PBPC mobilization in healthy child donors.
  • To assess the outcomes of child recipients undergoing allogeneic PBSC transplant.

Main Methods:

  • Eight pediatric patients with various malignancies received PBPC from HLA-identical or partially mismatched sibling donors.
  • Donors (aged 1-15 years) underwent G-CSF mobilization and leukapheresis.
  • Graft-versus-host disease (GvHD) prophylaxis included CsA with MTX or methylprednisolone.

Related Experiment Videos

Main Results:

  • No adverse effects were observed from G-CSF or the procedure.
  • All patients achieved successful engraftment with a median CD34(+) cell count of 5.18 x 10(6)/kg.
  • Good survival rates and low incidence of acute GvHD were reported after a median follow-up of 18 months.

Conclusions:

  • Allogeneic PBPC transplantation is a safe and successful procedure for pediatric donor-recipient pairs.
  • This method offers a viable treatment option for pediatric malignancies.